Adverse events, morbidity, and mortality at 1-month*.
| Event type | All (n=167) | DL (n=80) | SL/SLS (n=87) | p Value |
| Thromboembolic events | 24 (14.4%) | 15 (18.8%) | 9 (10.3%) | 0.130 |
| 11 (6.6%) | 9 (11.3%) | 2 (2.3%) | 0.027 |
| 8 (4.8%) | 4 (5.0%) | 4 (4.6%) | 1.000 |
| 5 (3.0%) | 2 (2.5%) | 3 (3.4%) | 1.000 |
| Intraprocedural rupture | 2 (1.2%) | 1 (1.3%) | 1 (1.1%) | 1.000 |
| Intracranial hemorrhage | 1 (0.6%) | 1 (1.3%) | 0 (0.0%) | 0.479 |
| Morbidity† | 5 (3.0%) | 3 (3.8%) | 2 (2.3%) | 0.671 |
| Mortality | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | NA |
*One patient withdrew his consent between the procedure and the 1-month follow-up.
†Modified Rankin Scale (mRS) score >2 if baseline ≤2. mRS +1 or more if baseline >2. mRS >2 and ruptured at baseline.